P2.17. EFfectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Apar Kishor Ganti
Meta Tag
Speaker Apar Kishor Ganti
Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy
WCLC 2023 conference
second-line small cell lung cancer
real-world evidence
oncogenic transcription inhibitor
accelerated approval
overall response rates
progression-free survival
time to next treatment
safety outcomes
Powered By